Development of BTK inhibitors for the treatment of B-cell malignancies

• Published in: Archives of pharmacal research Vol. 42; no. 2; pp. 171 - 181
• Main Author: Kim, Hyung-Ook
• Format: Journal Article
• Language: English
• Published: Seoul Pharmaceutical Society of Korea 01.02.2019; 대한약학회
• Subjects: Medicine; Pharmacology/Toxicology; Pharmacy; Review; 약학; BTK; BTK inhibitors; Ibrutinib; Noncovalent BTK inhibitors; B-cell malignancies
• ISSN: 0253-6269; 1976-3786
• DOI: 10.1007/s12272-019-01124-1

BTK is a key component of B-cell receptor signaling and functions as an important regulator of cell proliferation and survival in B-cell malignancies. The first-in-class BTK inhibitor ibrutinib is a small molecule drug that binds covalently to BTK and has been proved to be an effective treatment for various B-cell malignancies. However, it has off-target activities on non-BTK kinases that are related to side effects or might be translated into clinical limitations, with resistance to ibrutinib also reported. Much progress has been made in the development of more selective and second-generation BTK inhibitors. A recent shift in the mechanisms of action of BTK inhibitors is noteworthy, and novel inhibitors acting through noncovalent BTK inhibition are now being developed. This review describes key characteristics of ibrutinib, including current issues of its clinical use, and summarizes preclinical properties and clinical developments of second-generation BTK inhibitors for the treatment of B-cell malignancies. A review of novel noncovalent BTK inhibitors are also included.